Identification |
Name: | 2-Pyrrolidinecarboxamide,1-[[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-,(2S)- |
Synonyms: | 2-Pyrrolidinecarboxamide,1-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-,[2R-[2a(S*),3b]]-; Relcovaptan; SR 49059 |
CAS: | 150375-75-0 |
Molecular Formula: | C28H27 Cl2 N3 O7 S |
Molecular Weight: | 620.50088 |
InChI: | InChI=1/C28H27Cl2N3O7S/c1-39-23-12-10-17(15-24(23)40-2)41(37,38)33-21-11-9-16(29)14-19(21)28(36,18-6-3-4-7-20(18)30)25(33)27(35)32-13-5-8-22(32)26(31)34/h3-4,6-7,9-12,14-15,22,25,36H,5,8,13H2,1-2H3,(H2,31,34) |
Molecular Structure: |
|
Properties |
Flash Point: | 478.8°C |
Boiling Point: | 868°Cat760mmHg |
Density: | 1.499g/cm3 |
Refractive index: | 1.664 |
Biological Activity: | Potent and selective non-peptide vasopressin V 1A receptor antagonist; devoid of agonist activity. Displays high affinity and efficacy at both rat (K i = 1.6 nM) and human (K i = 1.1-6.3 nM) V 1A receptors. Potently antagonizes arginine vasopressin-induced effects in vitro (IC 50 = 3.7 nM for inhibition of human platelet aggregation) and is orally active in vivo . |
Flash Point: | 478.8°C |
Safety Data |
|
|